Summary
Gilead Sciences, Inc. (GILD) filed an 8-K report on September 29, 2020, detailing a significant material definitive agreement. The company entered into an underwriting agreement on September 23, 2020, to issue and sell a substantial aggregate principal amount of various senior notes, totaling $7.25 billion. These notes include both floating rate and fixed rate instruments with maturities ranging from 2021 to 2050. This debt issuance is a key event for investors to note, as it represents a significant capital raise for the company. The proceeds are likely intended to support ongoing operations, strategic initiatives, and potentially fund the previously announced acquisition of Immunomedics, Inc. Investors should consider the impact of this increased leverage on Gilead's financial structure and future interest expenses.
Key Highlights
- 1Gilead Sciences entered into an Underwriting Agreement on September 23, 2020, to issue and sell Notes.
- 2The total aggregate principal amount of Notes to be issued is $7.25 billion.
- 3The offering includes $1 billion in Floating Rate Notes (due 2021 and 2023).
- 4The offering includes $6.25 billion in Fixed Rate Senior Notes with maturities ranging from 2023 to 2050.
- 5The underwriters include Barclays Capital Inc. and Wells Fargo Securities, LLC.
- 6The report highlights that affiliates of the underwriters may be involved in financing for the acquisition of Immunomedics, Inc.
- 7The company is not an emerging growth company and has not elected to delay adoption of new accounting standards.